Tailoring systemic treatment in HER2-positive breast cancer

Tailoring systemic treatment in HER2-positive breast cancer

Authors	A. van der Voort
Supervisors	G.S. Sonke
Cosupervisors	R.M. Mann
Award date	13-06-2024
ISBN	9789465061061
Number of pages	223
Organisations	Faculty of Medicine (AMC-UvA)
Document type	PhD thesis
Language	English
Downloads	Thesis (complete) Front matter Chapter 1: General introduction and thesis outline Chapter 2: A randomized, open label, multicenter phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2- blockade for HER2-positive breast cancer: The TRAIN-2 study (BOOG 2012-03) Chapter 3: Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomized, phase 3 trial Chapter 4: Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2- positive breast cancer: A nationwide cohort analysis of pathologic response and 5-year survival Chapter 5: BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer Chapter 6: Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer Chapter 7: MRI guided optimization of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer: The multicenter phase 2 TRAIN-3 study (BOOG 2018-01) Chapter 8: Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: Study protocol for the phase 1b TRAIN-4 study Chapter 9: General discussion Chapter 10: Summary (English); Samenvatting (Nederlands) Author contributions per chapter; PhD portfolio; List of publications; Curriculum vitae; Dankwoord
Permalink to this page

Back

UvA-DARE

Digital Academic Repository

Tailoring systemic treatment in HER2-positive breast cancer